Annals of Surgical Oncology

, Volume 14, Issue 2, pp 759–765 | Cite as

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

  • Michael D’Angelica
  • Peter Kornprat
  • Mithat Gonen
  • Ki-Young Chung
  • William R. Jarnagin
  • Ronald P. DeMatteo
  • Yuman Fong
  • Nancy Kemeny
  • Leslie H. Blumgart
  • Leonard B Saltz



Bevacizumab (bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection.


Computerized pharmacy records were used to identify all patients who received bev between January 2004 and June 2005. Patients who underwent hepatectomy for colorectal metastases and received bev within 12 weeks of surgery were identified and compared with a group of matched historical controls.


Thirty-two patients underwent hepatic resection of colorectal cancer metastases and received bev within the specified perioperative period. Sixteen patients received bev before surgery and 24 received bev after surgery. A subset of eight patients received bev both before and after surgery. The median time between bev administration and surgery was 6.9 weeks before (range, 3–15 weeks) and 7.4 weeks after (range, 5–15 weeks). Perioperative complications occurred in 13 patients (40.6%), two of which were considered major complications. There was no statistically significant difference in perioperative morbidity and severity of complications when compared with a set of matched controls.


Clinical experience thus far does not indicate a statistically significantly increased risk of perioperative complications with the incorporation of bev into pre- and/or postoperative treatment paradigms. Given the long half-life of bev and the potential for anti-VEGF therapy to impede wound healing and/or liver regeneration, we continue to favor a window of 6 to 8 weeks between bev administration and surgery.


Colorectal metastases Hepatectomy Bevacizumab Bev Perioperative morbidity 


  1. 1.
    Fong Y, Fortner J, Sun R, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–30PubMedCrossRefGoogle Scholar
  2. 2.
    Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRefGoogle Scholar
  3. 3.
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905–14PubMedCrossRefGoogle Scholar
  4. 4.
    Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888–96PubMedCrossRefGoogle Scholar
  5. 5.
    Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–37PubMedCrossRefGoogle Scholar
  6. 6.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRefGoogle Scholar
  7. 7.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) Study E3200 (abstract 2). Proc Am Soc Clin Oncol 2005; 23:16SGoogle Scholar
  8. 8.
    Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685–93PubMedCrossRefGoogle Scholar
  9. 9.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRefGoogle Scholar
  10. 10.
    Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706–12PubMedCrossRefGoogle Scholar
  11. 11.
    Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853–5PubMedCrossRefGoogle Scholar
  12. 12.
    Scappaticci F, Fehrenbacher L, Cartwright J, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery (abstract 3530). Proc Am Soc Clin Oncol 2004; 22:14SGoogle Scholar
  13. 13.
    Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg 2002; 236:397–407PubMedCrossRefGoogle Scholar
  14. 14.
    Couinaud C. Bases anatomiques des hepatectomies gauche et droite reglees. J Chir 1954; 70:933–66Google Scholar
  15. 15.
    Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235:803–13PubMedCrossRefGoogle Scholar
  16. 16.
    Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502–8PubMedCrossRefGoogle Scholar
  17. 17.
    Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR-2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553–63PubMedGoogle Scholar
  18. 18.
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 7:58–62CrossRefGoogle Scholar
  19. 19.
    Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39–50PubMedGoogle Scholar
  20. 20.
    Furnus CC, Inda AM, Andrini LB, et al. Chronobiology of the proliferative events related to angiogenesis in mice live regeneration after partial hepatectomy. Cell Biol Int 2003; 27:383–6PubMedCrossRefGoogle Scholar
  21. 21.
    Kraizer Y, Mawasi N, Saegal J, et al. Vascular endothelial growth factor and angiopoetin in liver regeneration. Biochem Biophys Res Commun 2001; 287:209–15PubMedCrossRefGoogle Scholar
  22. 22.
    LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890–3PubMedCrossRefGoogle Scholar
  23. 23.
    Haroon Z, Amin K, Saito W, et al. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 2002; 1:121–6PubMedGoogle Scholar
  24. 24.
    Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542PubMedCrossRefGoogle Scholar
  25. 25.
    Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005; 23:2574–6PubMedCrossRefGoogle Scholar
  26. 26.
    Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti–vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843–50PubMedGoogle Scholar
  27. 27.
    Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237:860–70PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Michael D’Angelica
    • 1
  • Peter Kornprat
    • 1
  • Mithat Gonen
    • 2
  • Ki-Young Chung
    • 3
  • William R. Jarnagin
    • 1
  • Ronald P. DeMatteo
    • 1
  • Yuman Fong
    • 1
  • Nancy Kemeny
    • 3
  • Leslie H. Blumgart
    • 1
  • Leonard B Saltz
    • 3
  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Medical OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations